Login / Register Order My Items
mob-logo
Contact Us
800.227.0627
Contact Us Quote Order Login / Register

5′ & 3′ Terminal Caps for DNA & RNA Oligonucleotides

Custom terminal caps and end modifications for blocking, conjugation, affinity capture, delivery, mRNA capping, and therapeutic research workflows.

3′ End Blockers 5′ Functional Handles Cholesterol / GalNAc Cap 0 / Cap 1 / Cap 2 ISO 9001:2015 ISO 13485:2016
Request a Quote View Terminal Cap Tables
Talk to a chemist Request a quote
Overview Selection Guide End Blockers Functional Caps Therapeutic Caps RNA Caps Chemistry & QC Contact
Overview

Terminal Caps for Stability, Functionality & Delivery

Terminal modifications are added to the 5′ or 3′ ends of DNA and RNA oligonucleotides to control stability, nuclease resistance, polymerase extension, conjugation, affinity capture, delivery, or mRNA translation behavior.

Bio-Synthesis offers a broad range of 5′ and 3′ terminal modifications for DNA and RNA oligonucleotides used in diagnostics, qPCR, sequencing, antisense, siRNA, aptamer, CRISPR, mRNA, and therapeutic research. Available options include end blockers, affinity tags, fluorophores, amino and thiol conjugation handles, PEG and lipid caps, GalNAc delivery ligands, and advanced mRNA cap structures.

Our scientific team can help identify the optimal terminal modification strategy based on stability requirements, conjugation chemistry, delivery goals, enzyme compatibility, purification needs, and downstream application workflows. If the terminal cap or conjugate you need is not listed below, Bio-Synthesis can often support custom modification development and specialized synthesis requests.

3′ End Blockers

5′ Functional Handles

PEG & Lipid Caps

Cholesterol / GalNAc

mRNA Cap 0 / 1 / 2

RNA End States

Terminal Cap Selection Guide

Browse Terminal Caps by Function

Start with what the terminal modification needs to accomplish, then jump directly to the matching cap category. Each section includes available options, typical uses, and design notes.

⛔

Prevent Extension or Degradation

Jump to 3′ blockers and spacer caps used to stop polymerase extension, reduce exonuclease trimming, and stabilize probes.

View End Blockers →

🔗

Add a Functional Handle

Explore amino, thiol, azide, biotin, FAM, and PEG terminal handles for labeling, capture, immobilization, and conjugation.

View Functional Caps →

🎯

Support Delivery or PK

Review cholesterol, GalNAc, PEG, LNA, and cEt terminal options used to support uptake, targeting, and stability.

View Therapeutic Caps →

🧬

Define RNA End State

Compare mRNA caps and RNA terminal phosphate states for translation, ligation, innate sensing, and RNA biology workflows.

View RNA Caps →

End Blockers

End Blockers for Stability & Nuclease Resistance

End blockers are terminal modifications added to DNA/RNA oligonucleotides to prevent exonuclease degradation or unwanted polymerase extension. They are widely used in ASOs, siRNA, PCR/qPCR blockers, diagnostic probes, and sequencing adapters.

Product / Modification Function Applications Code
3′-CPR II Strong 3′ nuclease block. ASO/siRNA stabilization. [3′-CPR-II]
3′-Phosphate Blocks 3′ exonucleases and polymerase extension. PCR blockers, antisense. [3′-PO₄]
3′-Inverted dT Reverse-oriented thymidine. General stabilization. [Inv-dT]
3′-Inverted abasic Inverted abasic sugar. Probes, antisense. [Inv-Ab]
3′-Spacer C3 / C6 / C12 Steric end block using alkyl linkers. Blocking probes. [C3|C6|C12]
Spacer 18 (HEG) Flexible ethylene-glycol spacer. Probe designs, FISH. [Sp18]
3′-dT / dA / dC / dG (2′–5′ linked) Non-natural 2′–5′ terminal linkage. Blocker probes. [3′-2′5′-dN]
2′,3′-dideoxyN (ddA/ddC/ddG/ddT) Lacks 2′ and 3′ OH; chain terminator. Sequencing, blocking. [ddN]
Technical notes for end blockers
  • For harsh nuclease environments, combine 3′ blocking with PS backbone at termini.
  • 2′–5′-linked bases and ddN are effective at preventing extension by most polymerases.
  • 3′-phosphate and inverted dT are practical options for blocking extension in many PCR/qPCR and probe workflows.
Functional & Conjugation Caps

Functional Handles & Conjugation Modifications

Terminal handles and labels support capture, imaging, coupling, surface attachment, labeling, sensor development, and downstream bioconjugation workflows.

Product / Modification Function Applications Code
3′-Amino (C3/C6) Reactive primary amine; also blocks extension. NHS-ester labeling; conjugation. [3′-NH₂]
3′-Biotin / 5′-Biotin-TEG Affinity capture tag. Pull-downs, ELISA, qPCR. [Bio-3′|Bio-5′]
5′-Amino / 5′-Amino-dT 5′ reactive amine, universal or on dT. Conjugation, immobilization. [5′-NH₂|5′-NH₂-dT]
5′-Thiol Terminal -SH for maleimide or gold coupling. Protein/PEG coupling; sensors. [5′-SH]
5′-Azide Click-ready azide. Bioorthogonal ligation, CuAAC/SPAAC. [5′-N₃]
3′-Fluorescein (FAM) Terminal fluorophore. qPCR, beacons, FISH. [FAM-3′]
3′-PEG (C3-PEG/C7-PEG) Hydrophilic spacer; PK tuning. Therapeutic constructs. [PEG-3′]
Technical notes for functional caps
  • For dense labeling, prefer TEG or PEG spacers to reduce steric hindrance.
  • Thiol or amine at 5′ pairs well with internal spacers for multivalent conjugation.
  • Azide and thiol caps are useful when site-specific post-synthetic conjugation is required.
Therapeutic Terminal Caps

Therapeutic Modifications for Delivery & PK Optimization

Therapeutic terminal caps can enhance cellular uptake, tissue targeting, distribution, metabolic stability, or pharmacokinetic behavior for ASO, siRNA, and related oligonucleotide research programs.

Product / Modification Function Applications Code
3′-Cholesterol Lipid anchor; uptake increase. ASO/siRNA delivery. [Chol-3′]
5′-Cholesterol Lipid anchor at the 5′ end. siRNA/ASO delivery. [Chol-5′]
3′-GalNAc (triantennary) ASGPR-mediated hepatocyte targeting. Liver-directed siRNA/ASO. [GalNAc-3′]
3′-PEG (length-tuned) Hydrophilicity and PK tuning. Stability and clearance control. [PEG-3′]
3′-LNA / cEt nucleoside Locked terminal base for protection. Gapmers, ASOs. [LNA-3′|cEt-3′]
Technical notes for therapeutic terminal caps
  • Pair terminal lipids with PS backbones and consider mixed PO/PS to tune exposure.
  • GalNAc clustering and linker geometry are critical for receptor avidity.
  • Terminal LNA or cEt can protect ends but should be balanced with target affinity and toxicity profile.
RNA-Specific Terminal Caps

RNA-Specific Terminal Caps & End States

RNA-specific caps include mRNA-style caps and terminal phosphate states for translation control, innate-immunity studies, ligation workflows, non-canonical NAD caps, and common 3′ RNA end states.

Product / Modification Function Applications Code
Cap 0 (m⁷GpppN) 5′–5′ m⁷G triphosphate; translation initiation. mRNA research. [Cap0]
Cap 1 (m⁷GpppNm) Cap 0 plus 2′-O-Me at first base; innate sensing decrease. Therapeutic mRNA, vaccines. [Cap1]
Cap 2 (m⁷GpppNmN) Cap 1 plus 2′-O-Me at second base. Advanced therapeutic mRNA research. [Cap2]
ARCA Anti-reverse cap analog; orientation-safe. Co-transcriptional capping. [ARCA]
CleanCap™ Co-transcriptional Cap 1/2 reagents; high efficiency. GMP IVT mRNA workflows. [CleanCap]
5′-Triphosphate (pppN) RIG-I agonist; modest protection. Innate-immunity studies, adjuvants. [5′-ppp]
5′-Diphosphate (ppN) Decapping intermediate; immunogenic. Innate sensing research. [5′-pp]
5′-Monophosphate (pN) Ligation-ready state. Small-RNA cloning, turnover. [5′-p]
5′-NAD Cap Non-canonical metabolite cap. Bacterial RNA regulation; synthetic biology. [NAD-Cap]
2′,3′-Cyclic Phosphate Blocks extension; requires RtcB for ligation. Degradation mapping; ligation workflows. [2′3′-cPO₄]
3′-Phosphate Blocks polymerase; convertible to 3′-OH. Controlled ligation; cloning. [3′-PO₄]
3′-Amino Reactive handle; also terminal block. Conjugation; surface coupling. [3′-NH₂]
3′-Biotin Affinity capture plus block. Pull-downs; selections. [Bio-3′]
Technical notes for RNA-specific caps
  • Therapeutic mRNA workflows often prioritize Cap 1 with optimized UTRs, poly(A) tail, and dsRNA removal.
  • Convert 3′ end states such as cPO₄, PO₄, or OH as required by ligase choice and workflow design.
  • Use 5′-ppp RNA intentionally when RIG-I activation is desired; avoid it for low-immunogenicity therapeutic constructs.
Design Strategy

Terminal Cap Selection Strategy

Choose by Function

  • Block extension: use 3′ phosphate, inverted dT, inverted abasic, spacer C3/C6/C12, or ddN.
  • Enable conjugation: use terminal amine, thiol, azide, or click-ready handles.
  • Support affinity capture: use 3′ or 5′ biotin with TEG spacing where needed.
  • Improve delivery: use cholesterol, GalNAc, PEG, or terminal LNA/cEt depending on application.

Design & Placement Notes

  • 3′ blockers are most common when preventing polymerase extension or exonuclease trimming.
  • 5′ handles are useful for immobilization, conjugation, ligation, and surface attachment.
  • Spacer choice can reduce steric hindrance for capture tags, fluorophores, and conjugates.
  • RNA cap choice should match translation, innate sensing, and IVT workflow requirements.
Chemistry & Quality

Chemistry, Purification & QC Documentation

Chemistry Support

  • Supports 5′ and 3′ terminal caps, blockers, affinity tags, fluorophores, and reactive handles.
  • RNA-specific terminal phosphate states and mRNA capping strategies available by workflow.
  • Custom linker, spacer, lipid, GalNAc, PEG, and specialty conjugation planning available.

Purification Options

  • RP-HPLC, IE-HPLC, PAGE, dual-HPLC, or RNase-free workflows depending on oligo type.
  • Additional purification planning for terminal dyes, conjugates, RNA caps, or difficult sequences.
  • Formulation, aliquoting, plate formatting, and concentration normalization available.

QC & Documentation

  • Identity confirmation by mass spectrometry where compatible.
  • Purity documentation with HPLC traces and optional enhanced release QC.
  • Endotoxin, bioburden, RNase control, CoA, and stability support available by request.
Quality alignment: Bio-Synthesis supports ISO 9001 / ISO 13485-aligned workflows and GLP/GMP-like practices as scoped.

Frequently Asked Questions

FAQ

Which cap should I use for therapeutic mRNA?
Cap 1 is commonly used as a default for therapeutic mRNA workflows. Cap 2 may be considered when additional innate immune reduction is needed in sensitive systems.
Does 5′-triphosphate RNA have a role?
Yes. 5′-triphosphate RNA can intentionally activate RIG-I in immunology research. For therapeutic workflows, capping or conversion to monophosphate can help reduce immunogenicity.
Is an end blocker the same as a terminal cap?
All end blockers are terminal caps, but not all terminal caps are blockers. Some terminal caps are functional labels, conjugation handles, affinity tags, fluorophores, or delivery conjugates.
Which 3′ cap is best for blocking polymerase extension?
 Common choices include 3′ phosphate, inverted dT, inverted abasic, spacer C3/C6/C12, and ddN depending on assay design, nuclease environment, and polymerase compatibility.
Can terminal caps be combined with backbone or sugar modifications?
 Yes. Terminal caps are often combined with phosphorothioate backbones, 2′ sugar modifications, LNA/cEt residues, fluorescent labels, affinity tags, or conjugation handles.
What information should I provide for a quote?
 Include oligo type, sequence, desired 5′ or 3′ cap, scale, purification target, conjugation needs, QC requirements, and intended application.
More FAQ'sAll FAQ's
Contact & Quote Request

Need help selecting the right terminal modification?

For the fastest review, share your oligo type, sequence length, desired 5′ or 3′ cap, scale, purification target, conjugation needs, terminal end-state requirements, and intended application. Our scientific team can recommend the most suitable terminal modification strategy and provide a detailed quote.
Request a Quote Speak to a Scientist
Need help before quoting?
Email: info@biosyn.com
Phone: 800-227-0627 (US/CAN)
Phone: +001-972-420-8505 (INT)

Related Services

Explore supporting services for terminal-modified oligo synthesis, RNA capping, conjugation, siRNA, ASO, aptamer, and internal modification workflows.

Custom siRNA Custom RNA Conjugation Internal Modification RNA Terminal Caps

Quote Preparation Checklist

Include oligo type, sequence, 5′/3′ cap, end-state, scale, purification, conjugation needs, QC requirements, and timeline.

Oligo Type 5′ / 3′ Cap Scale Purification QC Needs

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links